Sirolimus inhibits key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- and SI/DES-ratio's

BACKGROUND: Sirolimus (SRL, Rapamycin) has been used successfully to inhibit restenosis both in drug eluting stents (DES) and after systemic application. The current study reports on the effects of SRL in various human in vitro/ex vivo models and evaluates the theoretical clinical relevance of the d...

Descripción completa

Detalles Bibliográficos
Autores principales: Voisard, Rainer, Zellmann, Svenja, Müller, Fabian, Fahlisch, Felicitas, von Müller, Lutz, Baur, Regine, Braun, Jürgen, Gschwendt, Jürgen, Kountides, Margaratis, Hombach, Vinzenz, Kamenz, Joachim
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1878500/
https://www.ncbi.nlm.nih.gov/pubmed/17498286
http://dx.doi.org/10.1186/1471-2261-7-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1878500/
https://www.ncbi.nlm.nih.gov/pubmed/17498286
http://dx.doi.org/10.1186/1471-2261-7-15

Ejemplares similares